Compare Bristol-Myers Squibb Co (BMY) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Raytheon Technologies Corp — how do they compare? Bristol-Myers Squibb Co trades at $58.41 (market cap $116.30B), while Raytheon Technologies Corp trades at $193.64 (market cap $260.44B). The key difference: Raytheon Technologies Corp is far larger — about 2.2× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | RTX | |
|---|---|---|
Market Cap | $116.30B | $260.44B |
Sector | Health | Industrials |
52-Week High | $62.37 | $212.16 |
52-Week Low | $42.60 | $148.68 |
Enterprise Value | $152.24B | $292.55B |
Dividend Yield | 4.42% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
RTX trades at $196.39, up 0.23% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $1.78 surpassing the $1.51 expectation. Revenue grew to $88.6B in 2025, and net income margin improved to 8.03%. The company secured a $515 million Navy contract for SPY-6 radars, highlighting defense sector strength. Cash flow from operations reached $10.57B in 2025, supporting dividend payments and strategic investments.
The outlook for RTX is positive, driven by robust defense contracts, earnings growth, and a consensus price target of $213. Risks include reliance on government spending, competitive pressures, and macroeconomic volatility. Institutional sentiment remains bullish with 69% buy ratings, but investors should monitor debt levels and execution on production targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
